ibuprofen has been researched along with Parkinson Disease in 13 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess associations between Parkinson disease (PD) and putatively protective factors-smoking, caffeine (coffee, tea, and soft drinks), and nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen, and naproxen)." | 7.74 | Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. ( Hancock, DB; Jewett, R; Martin, ER; Scott, BL; Scott, WK; Stacy, MA; Stajich, JM; Vance, JM, 2007) |
| " There was a dose-response relationship between tablets of ibuprofen taken per week and PD risk (p trend = 0." | 6.47 | Use of ibuprofen and risk of Parkinson disease. ( Ascherio, A; Chen, H; Gao, X; Schwarzschild, MA, 2011) |
| "The present study is to investigate the neuroprotective effect of ibuprofen by intranasal administration of mucoadhesive microemulsion (MMEI) against inflammation-mediated by dopaminergic neurodegeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD)." | 3.83 | Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model. ( Chuttani, K; Mandal, S; Mandal, SD; Sawant, KK; Subudhi, BB, 2016) |
| " After adjusting for the use of ibuprofen and other PD risk factors, subjects with preceding pain symptoms had a higher incidence of PD than those without pain at baseline, and the hazard ratio was 1." | 3.79 | Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study. ( Chang, HY; Chiang, YT; Lin, CH; Lin, HH; Wu, RM, 2013) |
| "To assess associations between Parkinson disease (PD) and putatively protective factors-smoking, caffeine (coffee, tea, and soft drinks), and nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen, and naproxen)." | 3.74 | Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. ( Hancock, DB; Jewett, R; Martin, ER; Scott, BL; Scott, WK; Stacy, MA; Stajich, JM; Vance, JM, 2007) |
| " There was a dose-response relationship between tablets of ibuprofen taken per week and PD risk (p trend = 0." | 2.47 | Use of ibuprofen and risk of Parkinson disease. ( Ascherio, A; Chen, H; Gao, X; Schwarzschild, MA, 2011) |
| "Ibuprofen in isolation was examined in four studies and was associated with a 27% reduction in risk (effect estimate 0." | 2.47 | Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. ( Ben-Shlomo, Y; Breen, K; Clarke, CE; Ives, N; Patel, S; Rees, K; Stowe, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Kuhlman, G | 1 |
| Auinger, P | 1 |
| Duff-Canning, S | 1 |
| Lang, A | 1 |
| Tanner, C | 1 |
| Marras, C | 1 |
| Singh, A | 1 |
| Tripathi, P | 1 |
| Singh, S | 1 |
| Lin, CH | 1 |
| Wu, RM | 1 |
| Chang, HY | 1 |
| Chiang, YT | 1 |
| Lin, HH | 1 |
| Mandal, S | 1 |
| Mandal, SD | 1 |
| Chuttani, K | 1 |
| Sawant, KK | 1 |
| Subudhi, BB | 1 |
| Samii, A | 1 |
| Etminan, M | 1 |
| Wiens, MO | 1 |
| Jafari, S | 1 |
| Gao, X | 2 |
| Chen, H | 2 |
| Schwarzschild, MA | 3 |
| Ascherio, A | 3 |
| Rees, K | 1 |
| Stowe, R | 1 |
| Patel, S | 1 |
| Ives, N | 1 |
| Breen, K | 1 |
| Clarke, CE | 1 |
| Ben-Shlomo, Y | 1 |
| He, B | 1 |
| Tang, J | 1 |
| Ding, Y | 1 |
| Wang, H | 1 |
| Sun, Y | 1 |
| Shin, JH | 1 |
| Chen, B | 1 |
| Moorthy, G | 1 |
| Qiu, J | 1 |
| Desai, P | 1 |
| Wild, DJ | 1 |
| Simon, KC | 1 |
| Jacobs, E | 1 |
| McCullough, ML | 1 |
| Calle, EE | 1 |
| Thun, MJ | 1 |
| Ton, TG | 1 |
| Heckbert, SR | 1 |
| Longstreth, WT | 1 |
| Rossing, MA | 1 |
| Kukull, WA | 1 |
| Franklin, GM | 1 |
| Swanson, PD | 1 |
| Smith-Weller, T | 1 |
| Checkoway, H | 1 |
| Hancock, DB | 1 |
| Martin, ER | 1 |
| Stajich, JM | 1 |
| Jewett, R | 1 |
| Stacy, MA | 1 |
| Scott, BL | 1 |
| Vance, JM | 1 |
| Scott, WK | 1 |
| Casper, D | 1 |
| Yaparpalvi, U | 1 |
| Rempel, N | 1 |
| Werner, P | 1 |
4 reviews available for ibuprofen and Parkinson Disease
| Article | Year |
|---|---|
Neuroinflammatory responses in Parkinson's disease: relevance of Ibuprofen in therapeutics.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Humans; Ibuprofen; Inflammation; Neu | 2021 |
NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Confid | 2009 |
Use of ibuprofen and risk of Parkinson disease.
Topics: Acetaminophen; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Confidence Interv | 2011 |
Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Ibuprofen; Neuroprotective Agents; Parkins | 2011 |
9 other studies available for ibuprofen and Parkinson Disease
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drug use and markers of Parkinson's disease progression: A retrospective cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Ibuprofen; Parkinson Disease; | 2023 |
Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Data Collection; Female; Human | 2013 |
Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adhesives; Administration, Intranasal; Animals; Corpus | 2016 |
Mining relational paths in integrated biomedical data.
Topics: Algorithms; Computers; Data Collection; Data Mining; Databases, Factual; Humans; Hypoglycemic Agents | 2011 |
Prospective study of statin use and risk of Parkinson disease.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Female; Follow-Up Studi | 2012 |
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; Human | 2005 |
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2006 |
Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Beverages; Caffeine; Case-Control Studies; F | 2007 |
Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro.
Topics: Acetaminophen; Animals; Aspirin; Cell Count; Cells, Cultured; Dopamine; Fetus; Glutamic Acid; Ibupro | 2000 |